News Quantified

ENLV – enlivex ltd. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares

Enlivex Therapeutics (ENLV) had its price target raised by HC Wainwright from $13.00 to $20.00. They now have a "buy" rating on the stock.

Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Form 6-K Enlivex Ltd. For: Apr 08

Form 6-K Enlivex Ltd. For: Mar 26

Form 20-F Enlivex Ltd. For: Dec 31

Form 6-K Enlivex Ltd. For: Mar 25

Form 6-K Enlivex Ltd. For: Mar 24

Top News Gainers

7/16 Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange 13.1%

3/13 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. 10.8%

11/14 Form 6-K Enlivex Therapeutics For: Nov 14 10.5%

6/24 Form EFFECT Enlivex Therapeutics 9.2%

3/20 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. 9.0%

9/23 First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference 7.2%

11/20 Form 424B5 Enlivex Therapeutics 6.9%

3/9 Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment 5.6%

11/18 Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis 5.3%

7/10 Form 424B3 Enlivex Therapeutics 4.5%

Top News Decliners

3/18 Form 6-K Enlivex Therapeutics For: Mar 18 -29.3%

2/24 Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms [MarketWatch] -26.0%

10/7 Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop -19.3%

10/8 European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment -12.0%

3/5 Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering -9.7%

3/26 Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing -9.6%

10/10 Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies -9.4%

6/6 Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients -8.3%

1/23 Form 20-F/A Enlivex Therapeutics For: Dec 31 -8.2%

3/3 Form 424B5 Enlivex Therapeutics -6.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day